Literature DB >> 7679708

Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.

B F Haynes1, L O Arthur, P Frost, T J Matthews, A J Langlois, T J Palker, M K Hart, R M Scearce, D M Jones, C McDanal.   

Abstract

The fusogenic (F) domain of human immunodeficiency virus (HIV) gp41 envelope (env) protein has sequence similarities to many virus and mediates the fusion of HIV-infected cells. During a survey of the immunogenicity of HIV env peptides in chimpanzees, we have observed that HIV peptide immunogenicity was dramatically altered by the NH2-terminal synthesis of the gp41 F domain to an otherwise immunogenic peptide. We compared two hybrid peptide types comprised of T helper (Th) and B cell epitopes of HIV gp120 env protein for their immunogenicity in chimpanzees. The Th-B epitope hybrid peptides contained the HIV gp120 Th cell determinant, T1 (amino acids [aa] 428-440)-synthesized NH2 terminal to gp120 V3 loop peptides, which contain B cell epitopes that induce anti-HIV-neutralizing antibodies (SP10IIIB [aa 303-321] and SP10IIIB [A] [aa 303-327]). The F-Th-B peptide contained the HIV gp41 F domain of HIVIIIB gp41 (aa 519-530)-synthesized NH2 terminal to the Th-B peptide. Whereas Th-B peptides were potent immunogens for chimpanzee antibody and T cell-proliferative responses, the F-Th-B peptide induced lower anti-HIV gp120 T and B cell responses. Moreover, immunization of chimpanzees with F-Th-B peptide but not Th-B peptides induced a significant decrease in peripheral blood T lymphocytes (mean decrease during immunization, 52%; p < 0.02). Chimpanzees previously immunized with F-Th-B peptide did not respond well to immunization with Th-B peptide with T or B cell responses to HIV peptides, demonstrating that the F-Th-B peptide induced immune hyporesponsiveness to Th and B HIV gp120 env determinants. These observations raise the hypothesis that the HIV gp41 env F domain may be a biologically active immunoregulatory peptide in vivo, and by an as yet uncharacterized mechanism, promotes primate immune system hyporesponsiveness to otherwise immunogenic peptides.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679708      PMCID: PMC2190925          DOI: 10.1084/jem.177.3.717

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  Does the HIV envelope induce a chronic graft-versus-host-like disease?

Authors:  J Habeshaw; E Hounsell; A Dalgleish
Journal:  Immunol Today       Date:  1992-06

2.  Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.

Authors:  K B Cease; H Margalit; J L Cornette; S D Putney; W G Robey; C Ouyang; H Z Streicher; P J Fischinger; R C Gallo; C DeLisi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

3.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

Authors:  L A Lasky; G Nakamura; D H Smith; C Fennie; C Shimasaki; E Patzer; P Berman; T Gregory; D J Capon
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

4.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

5.  Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus.

Authors:  W R Gallaher
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

6.  Human T cell antigen expression by primate T cells.

Authors:  B F Haynes; D L Dowell; L L Hensley; I Gore; R S Metzgar
Journal:  Science       Date:  1982-01-15       Impact factor: 47.728

7.  The amino-terminal peptide of HIV-1 glycoprotein 41 interacts with human erythrocyte membranes: peptide conformation, orientation and aggregation.

Authors:  L M Gordon; C C Curtain; Y C Zhong; A Kirkpatrick; P W Mobley; A J Waring
Journal:  Biochim Biophys Acta       Date:  1992-08-25

8.  An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.

Authors:  H Takahashi; J Cohen; A Hosmalin; K B Cease; R Houghten; J L Cornette; C DeLisi; B Moss; R N Germain; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

9.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

10.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

View more
  5 in total

Review 1.  HIV vaccine development at Duke University Medical Center.

Authors:  B F Haynes; H X Liao; H F Staats; M S Alam; K J Weinhold; D C Montefiori
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  A GxxxG-like motif within HIV-1 fusion peptide is critical to its immunosuppressant activity, structure, and interaction with the transmembrane domain of the T-cell receptor.

Authors:  Omri Faingold; Tomer Cohen; Yechiel Shai
Journal:  J Biol Chem       Date:  2012-08-07       Impact factor: 5.157

3.  Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.

Authors:  Jinsong Zhang; S Munir Alam; Hilary Bouton-Verville; Yao Chen; Amanda Newman; Shelley Stewart; Frederick H Jaeger; David C Montefiori; S Moses Dennison; Barton F Haynes; Laurent Verkoczy
Journal:  J Immunol       Date:  2014-01-24       Impact factor: 5.422

4.  HIV-1 gp41 and TCRalpha trans-membrane domains share a motif exploited by the HIV virus to modulate T-cell proliferation.

Authors:  Tomer Cohen; Shmuel Jaffe Cohen; Niv Antonovsky; Irun R Cohen; Yechiel Shai
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

5.  Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

Authors:  Marcel Maier; Timothy J Seabrook; Noel D Lazo; Liying Jiang; Pritam Das; Christopher Janus; Cynthia A Lemere
Journal:  J Neurosci       Date:  2006-05-03       Impact factor: 6.167

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.